Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Makes Progress in the TAVI Space With Navitor
by Zacks Equity Research
Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Abbott's (ABT) MitraClip Device Shows Favorable Outcome
by Zacks Equity Research
Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $102.63, moving +1.79% from the previous trading session.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $100.83, moving -0.87% from the previous trading session.
Why Is Abbott (ABT) Down 7.7% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.55, marking a -0.14% move from the previous day.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Abbott (ABT) to Expand Vascular Device Line With New Buyout
by Zacks Equity Research
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges
by Zacks Equity Research
At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.
The Zacks Analyst Blog Highlights Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan
by Zacks Equity Research
Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan are included in this Analyst Blog.
Top Analyst Reports for Abbott Laboratories, Boeing & Diageo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), The Boeing Company (BA) and Diageo plc (DEO).
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.
Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat
by Zacks Equity Research
Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.
ZBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.
Pre-Markets Edge Lower With Q4 Earnings Underway
by Zacks Equity Research
Pre-Markets Edge Lower With Q4 Earnings Underway
Pre-Markets Sink on Quarterly Earnings Ruminations
by Mark Vickery
Between Microsoft's deceleration in its Azure cloud business and Boeing's huge bottom-line miss, we start the day with challenges ahead.
Abbott (ABT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
by Zacks Equity Research
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update
by Zacks Equity Research
Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.